Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 6/2011

01-06-2011 | Review Article

A Benefit-Risk Assessment of Dabigatran in the Prevention of Venous Thromboembolism in Orthopaedic Surgery

Authors: Dr Sam Schulman, Ammar Majeed

Published in: Drug Safety | Issue 6/2011

Login to get access

Abstract

Dabigatran etexilate is a novel orally administered anticoagulant that exerts its action through reversible direct thrombin inhibition. This anticoagulant has been approved for prophylaxis against venous thromboembolism (VTE) after hip or knee arthroplasty, and in a few countries also for atrial fibrillation. This article reviews the efficacy and safety of dabigatran for the prophylaxis of VTE-indication compared with data on the most common current regimen with low-molecular-weight heparin (LMWH), specifically enoxaparin.
Alternative prophylactic agents are also discussed. The results regarding efficacy and safety are very similar for dabigatran and LMWH. Bleeding and gastrointestinal reactions are the most frequently reported adverse events with a comparable incidence on LMWH and are probably the result of surgery and anaesthaesia. No adverse event that is specific for dabigatran has been observed in these studies, although dyspepsia has been reported as significantly more frequent than warfarin in long-term studies on other indications. The fact that dabigatran has no antidote has so far not been a problem in patients undergoing orthopaedic surgery. The use of the lower dose of dabigatran (150 mg) appears beneficial to reduce the risk of bleeding in patients over 75 years of age and in those with moderate renal impairment to avoid drug accumulation. The convenience of oral administration is an advantage for dabigatran over LMWH, particularly for extended prophylaxis up to 1 month after surgery. In conclusion, the benefit-risk profile of dabigatran is favourable for use as prophylaxis against VTE after major orthopaedic surgery with its convenient oral administration without need for laboratory monitoring and a low risk of bleeding or other adverse events.
Literature
1.
2.
Stangier J, Rathgen K, Stahle H, et al. The pharmaco-kinetics, pharmacodynamics and tolerability of dabiga-tran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007 Sep; 64(3): 292–303PubMedCrossRef
3.
4.
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009 Sep 17; 361(12): 1139–51PubMedCrossRef
5.
Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous throm-boembolism. N Engl J Med 2009 Dec 10; 361(24): 2342–52PubMedCrossRef
6.
7.
Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest 2008 Jun; 133 (6 Suppl.): 381S–453SPubMedCrossRef
8.
Haddad FS, Kerry RM, McEwen JA, et al. Unanticipated variations between expected and delivered pneumatic compression therapy after elective hip surgery: a possible source of variation in reported patient outcomes. J Arthroplasty 2001 Jan; 16(1): 37–46PubMedCrossRef
9.
Freedman KB, Brookenthal KR, Fitzgerald Jr RH, et al. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg Am 2000 Jul; 82-A(7): 929–38PubMed
10.
Brookenthal KR, Freedman KB, Lotke PA, et al. A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty. J Arthroplasty 2001 Apr; 16(3): 293–300PubMedCrossRef
11.
Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126 (3 Suppl.): 338S–400SPubMedCrossRef
12.
Kim YH, Oh SH, Kim JS. Incidence and natural history of deep-vein thrombosis after total hip arthroplasty: a prospective and randomised clinical study. J Bone Joint Surg Br 2003 Jul; 85(5): 661–5PubMed
13.
Quinlan DJ, Eikelboom JW, Dahl OE, et al. Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. J Thromb Haemost 2007 Jul; 5(7): 1438–43PubMedCrossRef
14.
Seagroatt V, Tan HS, Goldacre M, et al. Elective total hip replacement: incidence, emergency readmission rate, and postoperative mortality. BMJ 1991 Dec 7; 303(6815): 1431–5PubMedCrossRef
15.
Spencer FA, Lessard D, Emery C, et al. Venous thromboembolism in the outpatient setting. Arch Intern Med 2007 Jul 23; 167(14): 1471–5PubMedCrossRef
16.
Bjornara BT, Gudmundsen TE, Dahl OE. Frequency and timing of clinical venous thromboembolism after major joint surgery. J Bone Joint Surg Br 2006 Mar; 88(3): 386–91PubMedCrossRef
17.
18.
Anderson Jr FA, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003 Jun 17; 107 (23 Suppl. 1): I9–16PubMedCrossRef
19.
Piovella F, Wang CJ, Lu H, et al. Deep-vein thrombosis rates after major orthopedic surgery in Asia: an epide-miological study based on postoperative screening with centrally adjudicated bilateral venography. J Thromb Haemost 2005 Dec; 3(12): 2664–70PubMedCrossRef
20.
Leizorovicz A. Epidemiology of post-operative venous thromboembolism in Asian patients: results of the SMART venography study. Haematologica 2007 Sep; 92(9): 1194–200PubMedCrossRef
21.
Nicolaides AN, Kakkar VV, Field ES, et al. The origin of deep vein thrombosis: a venographic study. Br J Radiol 1971 Sep; 44(525): 653–63PubMedCrossRef
22.
Kakkar VV, Howe CT, Flanc C, et al. Natural history of postoperative deep-vein thrombosis. Lancet 1969 Aug 2; 2(7614): 230–2PubMedCrossRef
23.
Moser KM, Fedullo PF, LitteJohn JK, et al. Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis. JAMA 1994 Jan 19; 271(3): 223–5PubMedCrossRef
24.
Nielsen HK, Husted SE, Krusell LR, et al. Silent pulmonary embolism in patients with deep venous thrombosis: incidence and fate in a randomized, controlled trial of anticoagulation versus no anticoagulation. J Intern Med 1994 May; 235(5): 457–61PubMedCrossRef
25.
Huisman MV, Buller HR, ten Cate JW, et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest 1989 Mar; 95(3): 498–502PubMedCrossRef
26.
Dorfman GS, Cronan JJ, Tupper TB, et al. Occult pulmonary embolism: a common occurrence in deep venous thrombosis. AJR Am J Roentgenol 1987 Feb; 148(2): 263–6PubMed
27.
Williams JW, Britt LG, Eades T, et al. Pulmonary embolism after amputation of the lower extremity. Surg Gynecol Obstet 1975 Feb; 140(2): 246–8PubMed
28.
Cruickshank MK, Levine MN, Hirsh J, et al. An evaluation of impedance plethysmography and 125I-fibrinogen leg scanning in patients following hip surgery. Thromb Haemost 1989 Nov 24; 62(3): 830–4PubMed
29.
Comp PC, Spiro TE, Friedman RJ, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 2001 Mar; 83-A(3): 336–45PubMed
30.
Kahn SR, Ginsberg JS. Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch Intern Med 2004 Jan 12; 164(1): 17–26PubMedCrossRef
31.
Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004 May 27; 350(22): 2257–64PubMedCrossRef
32.
Lieberman JR, Hsu WK. Prevention of venous thrombo-embolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am 2005 Sep; 87(9): 2097–112PubMedCrossRef
33.
Dahl OE, Caprini JA, Colwell Jr CW, et al. Fatal vascular outcomes following major orthopedic surgery. Thromb Haemost 2005 May; 93(5): 860–6PubMed
34.
Warwick D. New concepts in orthopaedic thrombopro-phylaxis. J Bone Joint Surg Br 2004 Aug; 86(6): 788–92PubMedCrossRef
35.
National Institutes of Health. Prevention of venous thrombosis and pulmonary embolism. Natl Inst Health Consens Dev Conf Consens Statement 1986; 6(2): 1–8
36.
Lotke PA, Lonner JH. The benefit of aspirin chemoprophylaxis for thromboembolism after total knee arthroplasty. Clin Orthop Relat Res 2006 Nov; 452: 175–80PubMedCrossRef
37.
Howie C, Hughes H, Watts AC. Venous thromboembolism associated with hip and knee replacement over a ten-year period: a population-based study. J Bone Joint Surg Br 2005 Dec; 87(12): 1675–80PubMedCrossRef
38.
Turpie AG, Bauer KA, Eriksson BI, et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002 Sep 9; 162(16): 1833–40PubMedCrossRef
39.
Lieberman JR, Wollaeger J, Dorey F, et al. The efficacy of prophylaxis with low-dose warfarin for prevention of pulmonary embolism following total hip arthroplasty. J Bone Joint Surg Am 1997 Mar; 79(3): 319–25PubMed
40.
Lieberman JR, Sung R, Dorey F, et al. Low-dose warfarin prophylaxis to prevent symptomatic pulmonary embolism after total knee arthroplasty. J Arthroplasty 1997 Feb; 12(2): 180–4PubMedCrossRef
41.
Pellegrini Jr VD, Donaldson CT, Farber DC, et al. The John Charnley Award: prevention of readmission for venous thromboembolic disease after total hip arthroplasty. Clin Orthop Relat Res 2005 Dec; 441: 56–62PubMedCrossRef
42.
Pellegrini Jr VD, Donaldson CT, Farber DC, et al. The Mark Coventry Award: prevention of readmission for venous thromboembolism after total knee arthroplasty. Clin Orthop Relat Res 2006 Nov; 452: 21–7PubMedCrossRef
43.
Gangireddy C, Rectenwald JR, Upchurch GR, et al. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. J Vasc Surg 2007 Feb; 45(2): 335–41PubMedCrossRef
44.
White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003 Sep; 90(3): 446–55PubMed
45.
Warwick DJ, Whitehouse S. Symptomatic venous thromboembolism after total knee replacement. J Bone Joint Surg Br 1997 Sep; 79(5): 780–6PubMedCrossRef
46.
Leclerc JR, Gent M, Hirsh J, et al. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohortstudy of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group. Arch Intern Med 1998 Apr 27; 158(8): 873–8PubMedCrossRef
47.
Colwell Jr CW, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am 1999 Jul; 81(7): 932–40PubMed
48.
Dahl OE, Gudmundsen TE, Haukeland L. Late occurring clinical deep vein thrombosis in joint-operated patients. Acta Orthop Scand 2000 Feb; 71(1): 47–50PubMedCrossRef
49.
Heit JA, Elliott CG, Trowbridge AA, et al. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000 Jun 6; 132(11): 853–61PubMed
50.
Anderson DR, Wilson SJ, Blundell J, et al. Comparison of a nomogram and physician-adjusted dosage of warfarin for prophylaxis against deep-vein thrombosis after arthroplasty. J Bone Joint Surg Am 2002 Nov; 84-A(11): 1992–7PubMed
51.
Collins R, Scrimgeour A, Yusuf S, et al. Reduction in fatal pulmonary embolism and venous thrombosis by perio-perative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988 May 5; 318(18): 1162–73PubMedCrossRef
52.
Lassen MR, Borris LC, Christiansen HM, et al. Prevention of thromboembolism in 190 hip arthroplasties: comparison of LMW heparin and placebo. Acta Orthop Scand 1991 Feb; 62(1): 33–8PubMedCrossRef
53.
Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of deep vein thrombosis after major knee surgery: a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost 1992 Apr 2; 67(4): 417–23PubMed
54.
Levine MN, Gent M, Hirsh J, et al. Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism: a randomized trial in patients undergoing knee surgery. Arch Intern Med 1996; 156(8): 851–6PubMedCrossRef
55.
Hull RD, Pineo GF, Stein PD, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 2001 Nov 20; 135(10): 858–69PubMed
56.
Cohen AT, Bailey CS, Alikhan R, et al. Extended throm-boprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty: a meta-analysis. Thromb Haemost 2001 May; 85(5): 940–1PubMed
57.
Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001; 358(9275): 9–15PubMedCrossRef
58.
Samama CM, Vray M, Barre J, et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant. Arch Intern Med 2002; 162(19): 2191–6PubMedCrossRef
59.
Eriksson BI, Dahl OE, Ahnfelt L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost 2004 Sep; 2(9): 1573–80PubMedCrossRef
60.
Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005 Jan; 3(1): 103–11PubMedCrossRef
61.
Ho SJ, Brighton TA. Ximelagatran: direct thrombin inhibitor. Vasc Health Risk Manag 2006; 2(1): 49–58PubMedCrossRef
62.
Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007 Sep 15; 370(9591): 949–56PubMedCrossRef
63.
Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007 Nov; 5(11): 2178–85PubMedCrossRef
64.
Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009 Jan; 24(1): 1–9PubMedCrossRef
65.
Huo M, Eriksson B, Dahl O, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE-NOVATE II randomised trial [abstract no. 0564]. Haematologica 2010; 95 (Suppl. 2): 233
66.
Wolowacz SE, Roskell NS, Plumb JM, et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty: a meta-analysis. Thromb Haemost 2009 Jan; 101(1): 77–85PubMed
67.
Friedman RJ, Dahl OE, Rosencher N, et al. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res 2010 Sep; 126(3): 175–82PubMedCrossRef
68.
69.
Hanf W, Duntze J, Hida H, et al. The implication of a direct antithrombine in the appearance of (serious) postoperative acute respiratory distress. Ann Fr Anesth Reanim 2009 Oct; 28(10): 885–8PubMedCrossRef
70.
71.
Zauderer B. Age-related changes in renal function. Crit Care Nurs Q 1996 Aug; 19(2): 34–40PubMed
72.
Dahl OE, Kurth AA, Rosencher N, et al. Efficacy and safety profile of dabigatran etexilate compared with enoxaparin in primary venous thromboembolism prevention after total knee or hip replacement surgery in patients over 75 years [poster ID 437]. In: American Society of Hematology, 2008 [online]. Available from URL: http://​ash.​confex.​com/​ash/​2008/​webprogram/​Paper2885.​html [Accessed 2010 May 1]
73.
Dahl OE, Kurth AA, Rosencher N, et al. Efficacy and safety profile of dabigatran etexilate for the prevention of venous thromboembolism in moderately renally impaired patients after total knee or hip replacement surgery [poster ID 981]. In: American Society of Hematology, 2008 [online]. Available from URL: http://​ash.​confex.​com/​ash/​2008/​webprogram/​Paper2917.​html [Accessed 2010 May 1]
74.
van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor —interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010 Mar 29; 103(6): 1116–27PubMedCrossRef
75.
Kapoor A, Chuang W, Radhakrishnan N, et al. Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review. Pharmacoeconomics 2010 Jul 1; 28(7): 521–38PubMed
76.
Holmes M, Carroll C, Papaioannou D. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal. Health Technol Assess 2009 Sep; 13 Suppl. 2: 55–62PubMed
77.
78.
79.
McCullagh L, Tilson L, Walsh C, et al. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. Pharmacoeconomics 2009; 27(10): 829–46PubMedCrossRef
80.
Wolowacz SE, Roskell NS, Maciver F, et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clin Ther 2009 Jan; 31(1): 194–212PubMedCrossRef
81.
Wilke T, Neumann K, Klapper U, et al. Oral anticoagulation after major hip or knee replacement surgery: a process-driven managerial pharmacoeconomic analysis in German hospitals. Orthopade 2008 May; 37(5): 448–56PubMedCrossRef
82.
Turpie A, Bauer K, Eriksson B, et al. Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration. Thromb Haemost 2003 Aug; 90(2): 364–6PubMed
83.
Mesko JW, Brand RA, Iorio R, et al. Venous thromboembolic disease management patterns in total hip arthroplasty and total knee arthroplasty patients: a survey of the AAHKS membership. J Arthroplasty 2001 Sep; 16(6): 679–88PubMedCrossRef
84.
Mismetti P, Laporte S, Zufferey P, et al. Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta-analysis. J Thromb Haemost 2004 Jul; 2(7): 1058–70PubMedCrossRef
85.
Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008 Jun 26; 358(26): 2765–75PubMedCrossRef
86.
Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008 Jul 5; 372(9632): 31–9PubMedCrossRef
87.
Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008 Jun 26; 358(26): 2776–86PubMedCrossRef
88.
Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009 May 16; 373(9676): 1673–80PubMedCrossRef
89.
Huisman MV, Quinlan DJ, Dahl OE, et al. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes 2010 Nov 1; 3(6): 652–60PubMedCrossRef
90.
Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010 Mar 6; 375(9717): 807–15PubMedCrossRef
91.
Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009 Aug 6; 361(6): 594–604PubMedCrossRef
92.
Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010 Dec 23; 363(26): 2487–98PubMedCrossRef
93.
Struijk-Mulder MC, Ettema HB, Verheyen CC, et al. Comparing consensus guidelines on thromboprophylaxis in orthopedic surgery. J Thromb Haemost 2010 Apr; 8(4): 678–83PubMedCrossRef
94.
Gallus A, Raman K, Darby T. Venous thrombosis after elective hip replacement: the influence of preventive intermittent calf compression and of surgical technique. Br J Surg 1983 Jan; 70(1): 17–9PubMedCrossRef
95.
Samama CM, Clergue F, Barre J, et al. Low molecular weight heparin associated with spinal anaesthesia and gradual compression stockings in total hip replacement surgery. Arar Study Group. Br J Anaesth 1997 Jun; 78(6): 660–5PubMedCrossRef
96.
Francis CW, Pellegrini Jr VD, Marder VJ, et al. Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. JAMA 1992 Jun 3; 267(21): 2911–5PubMedCrossRef
97.
Silbersack Y, Taute BM, Hein W, et al. Prevention of deep-vein thrombosis after total hip and knee replacement: low-molecular-weight heparin in combination with intermittent pneumatic compression. J Bone Joint Surg Br 2004 Aug; 86(6): 809–12PubMedCrossRef
98.
McKenna R, Galante J, Bachmann F, et al. Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression. BMJ 1980 Feb 23; 280(6213): 514–7PubMedCrossRef
99.
Hull R, Delmore TJ, Hirsh J, et al. Effectiveness of intermittent pulsatile elastic stockings for the prevention of calf and thigh vein thrombosis in patients undergoing elective knee surgery. Thromb Res 1979; 16(1-2): 37–45PubMedCrossRef
100.
Haas SB, Insall JN, Scuderi GR, et al. Pneumatic sequential-compression boots compared with aspirin prophylaxis of deep-vein thrombosis after total knee arthroplasty. J Bone Joint Surg Am 1990 Jan; 72(1): 27–31PubMed
101.
Kaempffe FA, Lifeso RM, Meinking C. Intermittent pneumatic compression versus coumadin: prevention of deep vein thrombosis in lower-extremity total joint arthroplasty. Clin Orthop Relat Res 1991 Aug; 269: 89–97PubMed
Metadata
Title
A Benefit-Risk Assessment of Dabigatran in the Prevention of Venous Thromboembolism in Orthopaedic Surgery
Authors
Dr Sam Schulman
Ammar Majeed
Publication date
01-06-2011
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 6/2011
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/11587290-000000000-00000

Other articles of this Issue 6/2011

Drug Safety 6/2011 Go to the issue

Original Research Article

Risk of Depressive Episodes with Rimonabant

Editorial

Fraudulent and Substandard Medicines

Review Article

Quinolones

Original Research Article

Impact of a Pharmacotherapeutic Programme on Control and Safety of Long-Term Anticoagulation Treatment

Original Research Article

Prescription Patterns in Asthma Patients Initiating Salmeterol in UK General Practice

Original Research Article

Fatal Toxicity from Symptomatic Hyperlactataemia